Background: Circulating tumor DNA (ctDNA) is an emerging resource for the diagnosis and prognosis of various types of cancer. However, characteristics and clinical utility of ctDNA is still largely unknown, especially in patients with genitourinary (GU) cancers.
compliance rates were high (> 95.0% through Cycle 13 and ≥ 90.0% thereafter through Cycle 47) and similar across treatment groups. Patients with deteriorated EQ-5L VAS: (T7) ADT+AA+P, 61.1%; ADT+PBOs, 67.3%; (T10) ADT+AA+P, 57.5%; ADT+PBOs, 61.6%. Median time to deterioration of EQ-5D-5L VAS: (T7) ADT+AA+P, 9.2 months; ADT+PBOs, 5.6 months (HR = 0.81; 95% CI, 0.70-0.94; p < 0.004); (T10) ADT+AA+P, 12.9 months; ADT+PBOs, 8.3 months (HR = 0.83; 95% CI, 0.72-0.97; p = 0.015). Consistent benefit with ADT+AA+P was found across all subgroups for T7 and T10. ConCluSionS: These results confirm significant delay of degradation of health-related quality of life by adding AA+P to ADT in patients with mHSPC, and are consistent with the significant improvements in overall survival and radiographic progression-free survival observed in LATITUDE.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.